Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Benzinga2024-12-03

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488795068?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WabTFXB8jRSQ_oduZcYDxA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/358cb2db9b64fbec76ea20fdc090e88e","is_english":true,"pubTime":"2024-12-03 00:44","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488795068","market":"us","top_or_hot":-1,"title":"Why Is Senti Biosciences Stock Surging Over 400% On Monday?","media":"Benzinga","content":"<div>\n<p>Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-senti-biosciences-stock-surging-164425242.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Senti Biosciences Stock Surging Over 400% On Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Senti Biosciences Stock Surging Over 400% On Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 00:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-senti-biosciences-stock-surging-164425242.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-senti-biosciences-stock-surging-164425242.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/why-senti-biosciences-stock-surging-164425242.html","article_id":"2488795068","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WabTFXB8jRSQ_oduZcYDxA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/358cb2db9b64fbec76ea20fdc090e88e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488795068","pubTimestamp":1733157865,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Senti Biosciences, Inc.  stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells.Three AML patients have been treated at the lowest dose level  and, as of the data cutoff date of September 19, two achieved complete remission, confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells to normal ranges.In addition, both patients were assessed as measurable residual disease negative after treatment, defined as no detectable cancer cells in a bone marrow sample.SENTI-202 was generally well-tolerated with no dose-limiting toxicities and an adverse event profile consistent with other investigational NK cell therapies and patients with underlying AML receiving lymphodepleting chemotherapy.Concurrently, Senti Bios","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNTI":"Senti Biosciences, Inc.","BK4539":"次新股"},"translate_title":"为什么Senti Biosciences股价周一飙升超过400%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9},"content_text":"Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.\nThe company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia.\nSENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells.\nThree AML patients have been treated at the lowest dose level (1.0 billion CAR+ NK cells per dose) and, as of the data cutoff date of September 19, two achieved complete remission, confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells to normal ranges.\nIn addition, both patients were assessed as measurable residual disease negative after treatment, defined as no detectable cancer cells in a bone marrow sample.\nBoth patients maintain remission (4+ months and 3+ months, respectively).\nThe Safety Review Committee cleared the lowest dose cohort, and dose escalation continues at the 1.5 billion CAR+ NK cells/dose level.\nSENTI-202 was generally well-tolerated with no dose-limiting toxicities and an adverse event profile consistent with other investigational NK cell therapies and patients with underlying AML receiving lymphodepleting chemotherapy.\nSENTI-202 transgene was detected in the peripheral circulation of all three patients and all cycles, with a pharmacokinetic profile generally consistent with other investigational CAR-NK therapy levels.\nThe company expects to enroll approximately 20 patients in the Phase 1 trial. A higher dose cohort of 1.5 billion CAR+ NK cells/dose is actively enrolling.\nAdditional safety and efficacy data, including initial durability data, are expected in 2025.\nConcurrently, Senti Biosciences announced a private investment in public equity financing to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock, with gross proceeds of approximately $37.6 million.\nThe company has also granted a certain investor an option to purchase an additional 4,444 shares of Preferred Stock and accompanying warrants for gross proceeds of approximately $10.0 million.\nSenti Biosciences also announced that it has appointed Fran Schulz, an experienced biotechnology and financial executive, to the Senti Bio Board of Directors. Omid Farokhzad is departing from the Board in conjunction with Schulz’s appointment.\nPrice Action: SNTI stock is up 439% at $11.66 at last check Monday.\nRead Next:\n\nNovoCure’s Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients\n\nIllustration of Phrama lab worker created with MidJourney.\nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nThis article Why Is Senti Biosciences Stock Surging Over 400% On Monday? originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488795068"}